A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies.

A pediatric patient-derived xenograft (PDX) program created 388 models across 40+ diagnoses, including ultra-rare tumors, enabling detailed cancer biology and therapy studies.

• Why it matters: Pediatric cancers, especially rare types, lack representative preclinical models, limiting research and therapeutic development. Developing pediatric-specific PDXs addresses this critical gap, improving translational research.
• What they did: The team integrated PDX generation into clinical workflows, optimizing tissue collection and cryopreservation, and produced models from longitudinal samples over six years, with genomic validation confirming tumor fidelity.
• The result: This diverse PDX collection supports hypothesis-driven research, biomarker validation, and personalized therapy testing, exemplified by successful preclinical evaluation of targeted drugs and tumor-specific genetic alterations.